Summary
We examined the therapeutic effects of dietary exposure to 5-campestenone (24-methylcholest-5-en-3-one), an enone derivative of campesterol, in C57BL/KsJ-db/db mice, which are an animal model of obese type 2 diabetes. Blood glucose levels of db/db mice linearly increased from 270 to 720 mg/dl in 10 weeks, an approximately 7-fold difference from the levels of db/+m mice. The 0.3 % dietary exposure to 5-campestenone caused a marked reduction in blood glucose levels of 330 mg/dl after 10 weeks of feeding with a concomitant inhibition of glucose excretion in urine. Only slight efficacy was observed with 0.1 % dietary exposure to this chemical in db/db mice. Significant decreases of plasma triglyceride and plasma free fatty acid were also observed in db/db mice at a 0.3 % dose. However, feed efficiency and body-weight gain in db/db mice was improved by 5-campestenone. No obvious anomaly due to consumption of 5-campestenone was detected by necropsy or clinical observation.
Key words
5-Campestenone - Type 2 Diabetes Mellitus Model Animal - C57BL db/db Mouse - Hypoglycemic Activity - Plasma Insulin
References
-
1
Lee Y, Hirose H, Ohneda M, Johnson J H, MacGarry J D.
Beta-cell lipotoxicity in the pathogenesis of non-insulin-dependent diabetes mellitus of obese rats: Impairment in adipocyte-beta-cell-relationships. Proc Natl Acad Sci.
USA.
1994;
91
10878-10882
-
2
Randle P J, Arland P B, Hales C N, Newsholme E A.
The glucose fatty-acid cycle: Its role in insulin sensitivity and the metabolic disturbances of diabetes mellitus.
Lancet.
1963;
1
785-789
-
3
Boden G.
Role of fatty acids in the pathogenesis of insulin resistance and NIDDM.
Diabetes.
1997;
46
3-10
-
4
Suzuki K.
Anti-obesity effect of cholest-4-en-3-one, an intestinal catabolite of cholesterol, on mice.
J Nutr Sci Vitaminol.
1993;
39
537-543
-
5
Suzuki K, Shimizu T, Nakata T.
The cholesterol metabolite cholest-4-en-3-one and its 3-oxo derivatives suppress body weight gain, body fat accumulation and serum lipid concentration in mice.
Bioorg Med Chem Lett.
1998;
8
2133-2138
-
6 Suzuki K, Shimizu T, Nakata T. A medicament for treating and improving lipid metabolism. US patent 09/480 892. 2000
-
7
Parish E J, Luo C, Parish S, Heideprien R W.
Selective oxidation of steroidal homoallylic alcohols usig pyridium chlorochromate (PPC).
Synthetic Communications.
1992;
22
2839 -2847
-
8
Arakawa K, Ishihara T, Oku A, Nawano M, Ueta K, Kitamura K, Matsumoto M, Saito A.
Improved diabetic syndrome in C57BL/Ksj-db/db mice by oral administration of the Na+-glucose cotransporter inhibitor T-1095.
British J Pharmacol.
2001;
132
578-586
-
9
Tutwiler G F, Kirsch T, Bridi G.
A pharmacologic profile of McN-3495[N-(1-methyl-2-pyrrolidinylidene)-N′-phenyl-1-pyrrolidinecarboximidamide], a new, orally effective hypoglycemic agent.
Diabetes.
1978;
27
856-867
-
10
Sugiyama Y, Taketomi S, Tawada H, Meguro K, Ikeda H, Fujita T.
Selective potentiation of 5-methyl-2-(1-methylcyclohexyl)-4-oxazoleacetic acid (AD-4610) on glucose-induced secretion.
Horm Metab Res.
1988;
20
145-149
-
11
Ikeda H, Taketomi S, Sugiyama Y, Shimura Y, Sohda T, Meguro K, Fujita T.
Effects of pioglitazone on glucose and lipid metabolism in normal and insulin resistant animals.
Arznein-Forsch/ Drug..
Res.1990;
40 (I)
156-162
-
12
Sugiyama Y, Taketomi S, Shimura Y, Ikeda H, Fujita T.
Effects of pioglitazone on glucose and lipid metabolism in Wistar fatty rats.
Arznein-Forsch/Drug Res.
1990;
40 (I)
263-267
Kunio Suzuki
Obesity and Lipidemia Research Unit · RIKEN Institute
Wako · Saitama 351-0198 · Japan
